Kras(G12D) and p(53) Mutation Cause Primary intrahepatic Cholangiocarcinoma

James P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, New York 14642, USA.
Cancer Research (Impact Factor: 9.28). 02/2012; 72(6):1557-67. DOI: 10.1158/0008-5472.CAN-11-3596
Source: PubMed

ABSTRACT Intrahepatic cholangiocarcinoma (IHCC) is a primary cancer of the liver with an increasing incidence and poor prognosis. Preclinical studies of the etiology and treatment of this disease are hampered by the relatively small number of available IHCC cell lines or genetically faithful animal models. Here we report the development of a genetically engineered mouse model of IHCC that incorporates two of the most common mutations in human IHCC, activating mutations of Kras (Kras(G12D)) and deletion of p53. Tissue-specific activation of Kras(G12D) alone resulted in the development of invasive IHCC with low penetrance and long latency. Latency was shortened by combining Kras(G12D) activation with heterozygous or homozygous deletion of p53 (mean survival of 56 weeks vs. 19 weeks, respectively), which also resulted in widespread local and distant metastasis. Serial analysis showed that the murine models closely recapitulated the multistage histopathologic progression of the human disease, including the development of stroma-rich tumors and the premalignant biliary lesions, intraductal papillary biliary neoplasms (IPBN), and Von Meyenburg complexes (VMC; also known as biliary hamartomas). These findings establish a new genetically and histopathologically faithful model of IHCC and lend experimental support to the hypothesis that IPBN and VMC are precursors to invasive cancers.

  • [Show abstract] [Hide abstract]
    ABSTRACT: O-GlcNAcylation, an important O-linked glycosylation of cellular glycoproteins with a single molecule of N-acetylglucosamine (GlcNAc), is involved in regulation of many cellular processes. Alteration of O-GlcNAcylation is associated with the development and progression of many cancers. Here, we demonstrated aberrant O-GlcNAcylation in the cholangiocarcinoma (CCA) using immunohistochemistry of O-GlcNAc modified proteins (OGP), O-GlcNAc transferase (OGT) and N-acetylglucosaminidase (O-GlcNAcase or OGA). OGP expression was low in normal bile ducts corresponding with the low OGT and high OGA expression. In contrast, OGP was strongly expressed in CCA tissues together with the up-regulation of OGT and down-regulation of OGA. Moreover, elevation of O-GlcNAcylation was associated with non-papillary type CCA and poor survival outcome of CCA patients. Our study showed for the first time that O-GlcNAcylation is increased in CCA tissues and is associated with a poor patient outcome. The OGT expression level could be a useful prognostic indicator and inhibition of O-GlcNAcylation might be a therapeutic target for CCA.
    Asian Pacific journal of cancer prevention: APJCP 01/2012; 13 Suppl:101-5. DOI:10.7314/APJCP.2012.13.KKSuppl.101 · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT Cancers exhibit differences in metastatic behavior and drug sensitivity that correlate with certain tumor-specific variables such as differentiation grade, growth rate/extent and molecular regulatory aberrations. In practice, patient management is based on the past results of clinical trials adjusted for these biomarkers. Here, it is proposed that treatment strategies could be fine-tuned upfront simply by quantifying tumorigenic spatial (cell growth) and temporal (genetic stability) control losses, as predicted by genetic defects of cell-cycle-regulatory gatekeeper and genome-stabilizing caretaker tumor suppressor genes, respectively. These differential quantifications of tumor dysfunction may in turn be used to create a tumor-specific 'periodic table' that guides rational formulation of survival-enhancing anticancer treatment strategies.
    Future Oncology 03/2015; 11(5):785-800. DOI:10.2217/fon.14.315 · 2.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cholangiocarcinoma (CC) is divided into distal, perihilar, and intrahepatic CCs (ICCS), and are further subdivided into large bile duct ICC and peripheral ICC. In distal and perihilar CC and large duct ICC, biliary intraepithelial neoplasm (BilIN) and intraductal papillary neoplasm (IPN) have been proposed as precursor lesions. Peripheral ICC, bile duct adenoma (BDA), biliary adenofibroma (BAF), and von Meyenburg complexes (VMCs) are reportedly followed by development of ICCs. Herein, we surveyed these candidate precursor lesions in the background liver of 37 cases of peripheral ICC and controls (perihilar CC, 34 cases; hepatocellular carcinoma, 34 cases and combined hepatocellular cholangiocarcinoma, 25 cases). In the background liver of peripheral ICC, BDA and BAF were not found, but there were not infrequently foci of BDA-like lesions and atypical bile duct lesions involving small bile ducts (32.4% and 10.8%, resp.). VMCs were equally found in peripheral CCs and also control CCs. In conclusion, BDA, BAF, and VMCs are a possible precursor lesion of a minority of peripheral CCs, and BDA-like lesions and atypical bile duct lesions involving small bile ducts may also be related to the development of peripheral ICC. Further pathologic studies on these lesions are warranted for analysis of development of peripheral ICCs.
    04/2014; 2014:805973. DOI:10.1155/2014/805973